What does a cruise and blast protocol mean when using oral stanozolol?

Cruise and blast is a periodization strategy alternating between a higher-compound blast phase (typically 6–10 weeks) and a lower-exposure cruise phase (8–16 weeks). Oral stanozolol is introduced during the blast window to amplify anabolic output, then stepped down or removed entirely during the cruise to allow hepatic enzyme and hormonal marker normalisation before the next blast begins.

How long should the cruise phase last after a stanozolol blast?

Most structured cruise-and-blast practitioners observe a cruise phase at least equal in length to the preceding blast — typically 8 to 12 weeks. For stanozolol specifically, because its 17α-alkylated oral structure elevates liver enzymes during active use, the cruise phase length is often guided by when ALT and AST values return to within-range on a standard liver panel rather than by a fixed calendar target.

When is the right point to switch from a stanozolol blast back to cruise?

The switch from blast to cruise is typically triggered by one of three markers: the pre-planned blast duration ending (commonly six to eight weeks for oral stanozolol), liver enzyme readings approaching or exceeding two times the upper limit of normal, or clinical signs such as persistent joint dryness or lipid shifts. Kim Pharma's 10 mg denomination allows a stepped reduction over five to seven days rather than an abrupt cutoff.

Can the 10 mg tablet denomination be used to split doses across multiple administrations during a blast phase?

Yes — the 10 mg tablet format is specifically suited to multi-administration blast protocols. A practitioner targeting 30 mg per day during a blast can distribute three tablets across morning, midday, and evening windows, spreading hepatic processing load across multiple metabolic intervals. Each tablet delivers a verified 10 mg unit, so there is no need to cut or estimate fractional doses, which eliminates the dosing variability introduced by tablet splitting.

Why is the 10 mg concentration the preferred option for cruise and blast phase management over higher-denomination tablets?

The 10 mg per tablet denomination is the lowest single-unit oral stanozolol concentration available in this product group, making it the most granular dose-management tool across both blast and cruise phases. A 50 mg tablet forces all-or-nothing dose changes in 50 mg increments, while the 10 mg format allows one-tablet step-ups or step-downs that match the incremental scaling logic of structured cruise-and-blast programming without compound waste or fractional tablet handling. (2) angle_used

Established Brand

Kim Pharma

Stanozolol 10mg/tab 100 Tabletten by Kim Pharma

Name: Stanozolol 10mg/tab 100 Tablets by Kim Pharma
Brand: Kim Pharma
SKU: ORA-STAN-KIM-026
Price: 34.00 EUR
Availability: InStock

Kim Pharma Stanozolol 10mg/tab (100tabs) is a single-active-ingredient oral anabolic tablet engineered specifically for athletes who structure their training year around defined blast and cruise phases, where precise per-tablet dosing determines how cleanly each phase transitions to the next. Each 10 mg tablet provides the granular control required to scale exposure up during a blast phase and step it back down to a cruise-compatible level without compound switching or tablet splitting. Batch-specific HPLC potency verification and LAL endotoxin screening are completed at the production level before any pack enters distribution — documentation is available on request.

€34.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Delivers exactly 10 mg of stanozolol per tablet — the lowest single-unit denomination in this oral stanozolol group — enabling one-tablet dose adjustments between blast and cruise phases.
HPLC-verified potency at the finished-tablet stage ensures dose arithmetic committed to during programme planning reflects actual compound delivery per tablet.
17α-alkylated stanozolol structure provides oral bioavailability suitable for phase-defined blast inclusion without an injectable companion compound.
100-tablet pack volume supports a full six-to-eight-week blast phase inclusion with margin for phase-transition step-down tablets in a single purchase.
LAL endotoxin testing at the batch level, applied across Kim Pharma's oral tablet production, ensures contamination is not a confounding variable when interpreting liver panel data during a blast.
Single active ingredient formulation with no added anabolic co-agents allows practitioners to attribute cycle outcomes and adverse signals to stanozolol specifically within a multi-compound blast stack.

Phase	Dosage	Note
Blast Phase — Entry	20 mg/day (2 tablets)	Introduce stanozolol at week 1 of the blast; assess tolerance over the first 7 days before escalating
Blast Phase — Peak	30–40 mg/day (3–4 tablets)	Maintain for weeks 2–6; distribute tablets across 2–3 daily windows to spread hepatic load
Blast-to-Cruise Transition	Step down 10 mg every 2–3 days	Reduce by one tablet per step over 5–7 days until reaching cruise dose or full removal
Cruise Phase	0–10 mg/day (0–1 tablet)	Most cruise protocols remove stanozolol entirely; low-dose retention (10 mg) only under liver panel guidance
Inter-Blast Monitoring Window	0 mg (stanozolol off)	Allow ALT/AST normalisation; reintroduce stanozolol only when liver markers return to within-range values

Key takeaways

Structure stanozolol use around defined blast and cruise phases for sustainable long-term periodization.
Step down blast doses one 10 mg tablet at a time to manage the blast-to-cruise transition cleanly.
Cap oral stanozolol blast inclusion at six to eight weeks to limit cumulative hepatic enzyme exposure.
Verify liver panels at blast midpoint to determine whether the phase continues or exits early.
Request Kim Pharma's batch HPLC documentation to confirm potency across every cruise and blast cycle.

Stanozolol and the Cruise & Blast Framework

Kim Pharma Stanozolol 10mg/tab (100tabs) is an oral anabolic compound containing stanozolol as its sole active ingredient, formulated at a denomination that maps directly onto the dose-stepping demands of cruise-and-blast periodization. Cruise-and-blast describes a training strategy in which an athlete alternates between a higher-exposure blast phase — typically 6 to 10 weeks with elevated anabolic compound load — and a reduced-exposure cruise phase maintained between blasts, commonly lasting 8 to 16 weeks at a lower daily milligram total. Compared to flat-dose year-round use, this phased structure is widely regarded among advanced practitioners as a more sustainable long-term approach because it allows hormonal axes partial recovery intervals without requiring a full post-cycle restart.

How the 10 mg Denomination Serves Each Phase

The 10 mg tablet denomination makes stanozolol the adjustable lever within a cruise-and-blast programme. During a blast phase, practitioners typically introduce stanozolol at 20–40 mg per day on top of a base compound, using two to four tablets distributed across the day. When the blast window closes, daily stanozolol exposure can be scaled down one tablet at a time — a reduction of exactly 10 mg per step — until either a cruise-compatible maintenance figure is reached or the compound is removed entirely for the cruise interval. Kim Pharma's HPLC-verified tablet uniformity ensures that each 10 mg step carries the same analytical potency, so the dose arithmetic a practitioner commits to on paper reflects what is actually delivered per tablet.

Phase Transition and Hepatic Considerations

Stanozolol's oral 17α-alkylated structure produces measurable ALT and AST elevation that correlates with daily exposure magnitude and cumulative cycle length. In a cruise-and-blast context, this makes the blast phase duration for stanozolol a distinct planning variable: most practitioners cap oral stanozolol blast inclusion at six to eight weeks before stepping the compound out, using the cruise phase to allow hepatic enzyme normalisation before any subsequent blast. LAL endotoxin testing at the batch level, applied by Kim Pharma to its oral tablet line, rules out pyrogenic contamination as a confounding variable when practitioners interpret liver panel results during an active cycle.

Semantic Reference Points

Kim Pharma's HPLC process verifies finished-tablet potency against a certified stanozolol reference standard before batch release.
Cruise-and-blast periodization reduces total annual stanozolol milligram exposure compared to uninterrupted year-round use at equivalent daily doses.
The 10 mg denomination allows practitioners to reduce stanozolol daily intake by one tablet increments when transitioning from blast to cruise without compound switching.

Usage

Map the blast phase window on a calendar before starting — target a six-to-eight-week stanozolol inclusion period with a defined end date, not an open-ended run.
Begin at 20 mg per day during the first seven days of the blast phase to establish individual tolerance before considering a dose increase.
Distribute the daily tablet total across two or three administrations to prevent hepatic processing from concentrating in a single metabolic window.
At the planned end of the blast phase, reduce daily stanozolol intake by one 10 mg tablet every two to three days rather than stopping abruptly, completing the step-down over five to seven days.
Obtain a liver panel (ALT, AST, GGT) at the blast midpoint and again within one week of the final stanozolol tablet to establish a baseline for the cruise phase and confirm enzyme trend direction.
During the cruise phase, keep stanozolol removed until ALT and AST values are confirmed within-range before planning the next blast inclusion window.

Warnings

Contraindications: Stanozolol is contraindicated in individuals with active hepatic impairment, prostate or breast carcinoma, hypercalcaemia, or known hypersensitivity to the active ingredient. Women of childbearing potential should not use stanozolol due to virilisation risk. Individuals with pre-existing dyslipidaemia should be aware that stanozolol produces pronounced HDL suppression and LDL elevation.

Side Effects: Oral stanozolol commonly produces elevated hepatic transaminases (ALT, AST), HDL cholesterol reduction, LDL elevation, joint dryness linked to reduced synovial fluid, and androgenic effects including accelerated hair loss in genetically predisposed individuals. Hepatic effects are dose- and duration-dependent, making blast phase length a key management variable.

Monitoring: Obtain a full blood panel — including liver function tests (ALT, AST, GGT), fasting lipid profile, and haematocrit — before beginning a blast phase. Repeat liver function tests at blast midpoint and within one week of stopping stanozolol. If ALT or AST exceeds two times the upper limit of normal, exit the blast phase regardless of planned duration.

PCT: Post-blast and post-cycle testosterone axis recovery support is required when stanozolol is used within a blast stack that includes suppressive base compounds. Standard PCT agents (SERMs such as tamoxifen or clomiphene) should be initiated after the base compound's clearance window has passed, not immediately following stanozolol discontinuation alone, as stanozolol itself is not the primary suppressive agent in most blast stacks.

Frequently asked questions

What does a cruise and blast protocol mean when using oral stanozolol?: Cruise and blast is a periodization strategy alternating between a higher-compound blast phase (typically 6–10 weeks) and a lower-exposure cruise phase (8–16 weeks). Oral stanozolol is introduced during the blast window to amplify anabolic output, then stepped down or removed entirely during the cruise to allow hepatic enzyme and hormonal marker normalisation before the next blast begins.
How long should the cruise phase last after a stanozolol blast?: Most structured cruise-and-blast practitioners observe a cruise phase at least equal in length to the preceding blast — typically 8 to 12 weeks. For stanozolol specifically, because its 17α-alkylated oral structure elevates liver enzymes during active use, the cruise phase length is often guided by when ALT and AST values return to within-range on a standard liver panel rather than by a fixed calendar target.
When is the right point to switch from a stanozolol blast back to cruise?: The switch from blast to cruise is typically triggered by one of three markers: the pre-planned blast duration ending (commonly six to eight weeks for oral stanozolol), liver enzyme readings approaching or exceeding two times the upper limit of normal, or clinical signs such as persistent joint dryness or lipid shifts. Kim Pharma's 10 mg denomination allows a stepped reduction over five to seven days rather than an abrupt cutoff.
Can the 10 mg tablet denomination be used to split doses across multiple administrations during a blast phase?: Yes — the 10 mg tablet format is specifically suited to multi-administration blast protocols. A practitioner targeting 30 mg per day during a blast can distribute three tablets across morning, midday, and evening windows, spreading hepatic processing load across multiple metabolic intervals. Each tablet delivers a verified 10 mg unit, so there is no need to cut or estimate fractional doses, which eliminates the dosing variability introduced by tablet splitting.
Why is the 10 mg concentration the preferred option for cruise and blast phase management over higher-denomination tablets?: The 10 mg per tablet denomination is the lowest single-unit oral stanozolol concentration available in this product group, making it the most granular dose-management tool across both blast and cruise phases. A 50 mg tablet forces all-or-nothing dose changes in 50 mg increments, while the 10 mg format allows one-tablet step-ups or step-downs that match the incremental scaling logic of structured cruise-and-blast programming without compound waste or fractional tablet handling. (2) angle_used

Manufacturer

Kim Pharma's customer support model for its oral anabolic tablet range addresses a practical gap that structured blast-and-cruise athletes encounter more acutely than casual users: the need to verify product documentation across multiple consecutive purchasing cycles, not just at first purchase. Because blast-and-cruise programmes can span twelve months or longer with recurring stanozolol blast insertions, practitioners require consistent access to batch-specific HPLC potency data and LAL endotoxin results for every pack they receive — not a single certificate filed away from an earlier order. Kim Pharma's support infrastructure is configured to accommodate repeat documentation requests, connecting each new pack's lot number to its corresponding production batch record on demand. This operational stance — treating documentation access as a recurring service rather than a one-time onboarding step — is reflected in how the brand positions itself specifically toward athletes running structured, multi-phase annual programmes rather than isolated short cycles where a single verification event is sufficient.

Product details

Brand	Kim Pharma
Active ingredient	stanozolol
Also known as	Winstrol, Stano, Stanozolol Tablets, Stanozolol, Kim Pharma Winstrol
Strength	10 mg
Form	Tabletten
Pack size	100 pieces
Item number	ORA-STAN-KIM-026

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Lab Tested

Strombafort 10mg/tab 100 Tablets by Balkan Pharmaceuticals

Strombafort is an oral anabolic steroid built on a stanozolol backbone — a 17α-methylated, A-ring-modified dihydrotestosterone (DHT) derivative — formulated at 10 mg per tablet and supplied in a pack of 100 tablets by Balkan Pharmaceuticals. Its defining pharmacological character stems from partial androgen receptor (AR) agonism combined with an inability to aromatise, making estrogenic activity structurally impossible for this molecule. Every batch of Strombafort is released only after HPLC assay confirmation of active stanozolol content and LAL-method endotoxin testing; GMP-certified production at the Chișinău facility underpins both identity and purity.

€32.00

Pro-Winstrol 20mg/tab 50 Tablets by Beligas Pharmaceuticals

HPLC Verified

Pro-Winstrol 20mg/tab 50 Tabletten by Beligas Pharmaceuticals

Pro-Winstrol by Beligas Pharmaceuticals delivers stanozolol at 20 mg per tablet in a 50-tablet oral format, defined primarily by its predictable pharmacokinetic profile: an oral half-life of approximately 9 hours that supports structured twice-daily dosing for stable plasma concentrations. Compared to injectable stanozolol suspension — which carries a half-life closer to 24 hours — the oral form enables more responsive dose adjustments across a cycle. Chromatographic content verification is applied to every production batch; each tablet's active stanozolol quantity is confirmed against certified reference standards prior to lot release.

€45.00

StanoTrex Tablets 10mg/tab 100 Tablets by Concentrex Labs

Pharma Grade

StanoTrex Tablets 10mg/tab 100 Tabletten by Concentrex Labs

StanoTrex Tablets deliver stanozolol in a discrete oral tablet format at 10 mg per unit — a concentration engineered for straightforward dose calibration while the compound's systemic absorption, secured by 17α-alkylation, ensures reliable plasma exposure despite hepatic first-pass transit. Oral stanozolol undergoes partial attenuation through liver metabolism compared to aqueous injectable suspension, yet the alkylated molecular structure preserves sufficient active compound to maintain consistent anabolic signalling across each dosing interval. Each 100-tablet jar is manufactured within a GMP-certified facility, with finished-tablet potency confirmed by HPLC quantification against a certified stanozolol reference standard before any lot clears for release.

€36.00

Winstrol 50 10mg/tab 100 Tablets by Dragon-Pharma

Batch Tested

Winstrol 50 10mg/tab 100 Tabletten by Dragon-Pharma

Dragon-Pharma Winstrol 50 delivers stanozolol in 10 mg oral tablets — a precision-dosed format specifically suited to managing the receptor-level adaptation that occurs when androgen signalling is sustained beyond its productive window. The 10 mg per-tablet format allows incremental dose adjustment as practitioners respond to early signs of diminishing receptor responsiveness, a clinical reality that makes low-denomination tablets more strategically valuable than high-concentration alternatives during extended use. Each 100-tablet batch clears HPLC content verification and GMP Standard-certified process controls before a release certificate is issued, confirming declared potency as a measured fact rather than a label assumption.

€30.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00